普洛药业上半年营收、净利双降

Core Viewpoint - Pro Pharmaceutical's half-year report for 2025 indicates a decline in both revenue and net profit, attributed to external macroeconomic fluctuations and weak demand in the industry [1] Financial Performance - The company reported a revenue of 5.444 billion yuan, representing a year-on-year decrease of 15.31% [1] - The net profit attributable to shareholders was 563 million yuan, down 9.89% year-on-year [1] Business Operations - The API business faced pressure due to the industry's cyclical downturn and weak demand for related products [1] - Despite challenges, the company achieved effective cost reduction and efficiency improvements through robust supply chain management and operational stability [1]